Hypertension drug developer Retension (RTSN.US) IPO priced at $11-13 per share, aiming to raise $40 million.
Retension Pharmaceuticals (RTSN.US) announced the terms of its initial public offering (IPO) on Monday.
According to Golden Ten Data APP, US hypertension drug developer Retension Pharmaceuticals (RTSN.US) announced the terms of its initial public offering (IPO) on Monday. The company plans to issue 3.3 million shares at a price range of $11 to $13 per share, raising $40 million. Based on the midpoint of the offering price range, Retension's fully diluted market capitalization will reach $108 million.
Retension was founded in 2023 and is a clinical-stage biopharmaceutical company currently focused on developing a single product, RTN-001. This is a once-daily, oral PDE-5 inhibitor for the treatment of uncontrolled hypertension and resistant hypertension. First-generation PDE-5 inhibitors (such as Viagra) never achieved meaningful blood pressure-lowering effects. The company believes this is because such drugs have difficulty fully penetrating the central vascular system rich in smooth muscle, whereas RTN-001 has been redesigned to improve bioavailability and increase its distribution within these tissues.
This drug was initially developed by Surface Logix, then subsequently by Nano Terra, Kadmon, and Sanofi, until the current team reacquired its license in 2023, bringing data from 9 completed trials, including two phase 2 trials. In October 2025, the company started a phase 2b dose exploration trial involving 280 patients, with about 40% of patients enrolled so far, and preliminary data expected to be released in the first half of 2027.
Retension plans to list on Nasdaq under the stock code "RTSN", with Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. acting as joint underwriters for the transaction. Pricing is expected during the week of October 5, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The New Zealand Dollar edges off its low as the US Dollar slips
Encompass Health Opens Rehabilitation Hospital in Bangor, Maine
05:57 PM EDT, 10/06/2026 (MT Newswires) -- Encompass Health (EHC) said late Tuesday it has opened the Encompass Health Rehabilitation Hospital of Bangor in Bangor, Maine and the 50-bed inpatient rehabilitation hospital is now accepting patients. The hospital offers essential rehabilitation services to help patients recovering from strokes, brain injuries, spinal cord injuries, amputations and complex orthopedic conditions regain functional ability, independence and quality of life, the company said. Patients receive physical, occupational and speech therapy based on their individual needs.
Constellation Brands, the maker of Corona beer, exceeds market expectations in the second quarter thanks to strong demand
Reuters, October 6 - Constellation Brands (STZ.N) reported on Tuesday that its second-quarter profit and sales both exceeded market expectations, thanks to strong demand for its beer products such as Modelo Especial and Victoria, which effectively offset challenges facing the alcohol sector amid weak consumer sentiment. The company also announced that it had acquired SpikedAde, a ready-to-drink (RTD) company with vodka-based products, for at least $75 million, as part of its strategy to expand into new demand segments and strengthen its position in the fast-growing RTD category. Constellation Brands will pay $75 million upon the closing of the SpikedAde deal, and up to an additional $278 million over the next five years, depending on the brand’s performance and the company’s capital allocation priorities. The company’s beer business benefited this year from major sports events, as the FIFA World Cup and NBA Finals boosted viewing parties and social drinking occasions. According to data compiled by London Stock Exchange Group (LSEG), net sales for the quarter ended August 31 rose 6% to $2.63 billion, surpassing analysts’ average estimate of $2.54 billion. Adjusted earnings per share for the quarter were $3.74, above the expected $3.56. The wine and spirits business reported quarterly net sales growth of 17%, while beer increased by 5%. Constellation Brands reaffirmed its fiscal 2027 performance outlook: adjusted earnings per share between $11.20 and $11.90, with organic net sales expected to range from a 1% decline to a 1% increase. The company lowered its annual operating margin forecast from the previous 32%-33% range to between 31% and 32%. Its stock fell 4.5% in after-hours trading, with a year-to-date drop of about 16%. In April, the company withdrew its fiscal 2028 performance outlook, citing a turbulent operating environment and uncertain near-term prospects.
Kraft Heinz General Counsel Angel S. Willis resigns effective Oct. 20
Kraft Heinz EVP, Global General Counsel and Corporate Affairs Officer Angel S. Willis will resign effective Oct. 20, 2026. Willis notified the company on Oct. 2, 2026, citing plans to pursue other opportunities. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Kraft Heinz Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001637459-26-000067), on October 06, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
